Testing of viscous anti-HIV microbicides using Lactobacillus.
The development of topical microbicides for intravaginal use to prevent HIV infection requires that the drugs and formulated products be nontoxic to the endogenous vaginal Lactobacillus. In 30min exposure tests we found dapivirine, tenofovir and UC781 (reverse transcriptase inhibitor anti-HIV drugs) as pure drugs or formulated as film or gel products were not deleterious to Lactobacillus species; however, PSC-RANTES (a synthetic CCR5 antagonist) killed 2 strains of Lactobacillus jensenii. To demonstrate the toxicity of formulated products a new assay was developed for use with viscous and non-viscous samples that we have termed the Lactobacillus toxicity test. We found that the vortex mixing of vaginal Lactobacillus species can lead to reductions in bacterial viability. Lactobacillus can survive briefly, about 2s, but viability declines with increased vortex mixing. The addition of heat inactivated serum or bovine serum albumin, but not glycerol, prevented the decrease in bacterial viability. Bacillus atrophaeus spores also demonstrated loss of viability upon extended mixing. We observed that many of the excipients used in film formulation and the films themselves also afford protection from the killing during vortex mixing. This method is of relevance for toxicity for cidal activities of viscous products.
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. bjm4@pitt.edu
B J
BJ
Moncla
K
K
Pryke
L C
LC
Rohan
H
H
Yang
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D000891:Anti-Infective Agents, Local / Q000737:chemistry / Q000494:pharmacology*; D002417:Cattle; D018946:Chemokine CCL5 / Q000494:pharmacology; D015169:Colony Count, Microbial; D005079:Excipients / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D005663:Furans / Q000494:pharmacology; D006801:Humans; D007778:Lactobacillus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D063065:Organophosphonates / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012710:Serum Albumin, Bovine; D000068698:Tenofovir; D013854:Thioamides; D014621:Vagina / Q000382:microbiology; D014783:Viscosity
D000813:Anilides; D019380:Anti-HIV Agents; D000891:Anti-Infective Agents, Local; D018946:Chemokine CCL5; D005079:Excipients; D005663:Furans; D063065:Organophosphonates; D011743:Pyrimidines; C492865:RANTES, N(alpha)-(n-nonanoyl)-desSer(1)-(thioproline(2),cyclohexylglycine(3))-; D013854:Thioamides; D012710:Serum Albumin, Bovine; D000068698:Tenofovir; D000225:Adenine; C100668:UC-781; C481671:Dapivirine